Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIB1/iSCIB1+ with checkpoint inhibitors in advanced melanoma
NCT04079166Phase 2Active, not recruiting
- Sponsor
- Scancell
- Start
- Aug 2019
- Primary completion
- Jan 2027
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of SCIB1, iSCIB1+ in melanoma, sponsored by Scancell. Started Aug 2019; status: active, not recruiting.
02
Drugs
SCIB1iSCIB1+
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04079166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04079166.